Norges Bank Revance Therapeutics, Inc. Transaction History

Norges Bank

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.34 - $4.73 $376,740 - $761,530	161,000 New	161,000 $413,000
Q4 2023 Feb 09, 2024	BUY	$5.81 - $11.2 $935,409 - $1.8 Million	161,000 New	161,000 $1.42 Million
Q3 2023 Nov 13, 2024	BUY	$11.47 - $25.07 $1.85 Million - $4.04 Million	161,000 New	161,000 $1.85 Million
Q1 2023 May 15, 2024	BUY	$18.36 - $35.27 $2.96 Million - $5.68 Million	161,000 New	161,000 $5.19 Million
Q4 2022 Feb 14, 2023	BUY	$18.32 - $30.66 $2.95 Million - $4.94 Million	161,000 New	161,000 $2.97 Million

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.